Etretinate in pustular psoriasis of plams and soles
- 1 November 1985
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 113 (5) , 581-585
- https://doi.org/10.1111/j.1365-2133.1985.tb02382.x
Abstract
In a double-blind controlled study of patients with pustular psoriasis of palms and soles who were allocated at random to etretinate or placebo, we found that etretinate improved the condition as assessed by pustule count and overall clinical responses. Side-effects occurred but were accepted by the patients in the short-term. The clinical usefulness of etretinate in this condition will depend on time to relapse, and whether this can be prevented or postponed by continuous treatment. Toxicity in the long-term will also be important.This publication has 6 references indexed in Scilit:
- A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasisBritish Journal of Dermatology, 1984
- A Randomized Trial of Etretinate (Tigason®) in Palmoplantar PustulosisDermatology, 1983
- Efficacy of Etretinate (Tigason®) in Clearing and Prevention of Relapse of Palmoplantar PustulosisDermatology, 1983
- Oral Treatment of Pustulosis Palmo-Plantaris with a New Retinoid, Ro 10-9359Dermatology, 1979